We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

52 hedge funds and large institutions have $127M invested in VistaGen Therapeutics in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,238% more capital invested

Capital invested by funds: $2.39M → $127M (+$125M)

600% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

86% more funds holding

Funds holding: 28 → 52 (+24)

1.48% more ownership

Funds ownership: 0.15% → 1.63% (+1.5%)

Holders
52
Holders Change
+24
Holders Change %
+85.71%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
8
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$7.96M
2
VA
VR Adviser
New York
+$7.96M
3
ACP
Acuta Capital Partners
California
+$6.38M
4
O
OrbiMed
New York
+$6.38M
5
Franklin Resources
Franklin Resources
California
+$5.31M

Top Sellers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
-$92K
2
Goldman Sachs
Goldman Sachs
New York
-$48.6K
3
LPL Financial
LPL Financial
California
-$21.3K
4
RC
RBF Capital
California
-$17K
5
TRCT
Tower Research Capital (TRC)
New York
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$187K -$7.91K -310 -9%
Goldman Sachs
27
Goldman Sachs
New York
$163K -$48.6K -1,906 -40%
OFA
28
Oak Family Advisors
Illinois
$163K +$71.4K +2,797 New
SSA
29
Schonfeld Strategic Advisors
New York
$152K +$66.4K +2,603 New
Capstone Investment Advisors
30
Capstone Investment Advisors
New York
$139K +$60.9K +2,386 New
QSS
31
Quantitative Systematic Strategies
Florida
$137K +$59.9K +2,346 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$112K +$49.1K +1,923 New
Parallax Volatility Advisers
33
Parallax Volatility Advisers
California
$86K – – –
BlackRock
34
BlackRock
New York
$66K +$1.1K +43 +4%
LPL Financial
35
LPL Financial
California
$49K -$21.3K -834 -50%
FAIM
36
Financial Advocates Investment Management
Washington
$45K – – –
Koshinski Asset Management
37
Koshinski Asset Management
Illinois
$44K +$2.37K +93 +14%
Carson Wealth (CWM LLC)
38
Carson Wealth (CWM LLC)
Nebraska
$43K – – –
UBS Group
39
UBS Group
Switzerland
$39K -$153 -6 -0.9%
GBA
40
Garrison Bradford & Associates
New York
$39K – – –
CSS
41
Cubist Systematic Strategies
Connecticut
$38K +$16.7K +656 New
NA
42
NewEdge Advisors
Louisiana
$37K +$6.2K +243 +61%
HFM
43
Hartford Financial Management
Connecticut
$31K – – –
SG Americas Securities
44
SG Americas Securities
New York
$29K +$12.5K +490 New
IAN
45
Integrated Advisors Network
Texas
$29K +$12.8K +500 New
Morgan Stanley
46
Morgan Stanley
New York
$24K – – –
JMPWA
47
JP Morgan Private Wealth Advisors
California
$19K – – –
NAS
48
Nicolet Advisory Services
Wisconsin
$19K – – –
SB
49
Samsara BioCapital
California
$3.18K +$1.4M +54,679 New
GIA
50
Goodwin Investment Advisory
Georgia
$2K +$842 +33 New
1
2
3

VTGN Hedge Fund Activity: Q4 2020 in Review

52 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2020, worth a combined $127M — up 5,238% from $2.39M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VTGN positions and 4 closed out — a net gain of 24 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $7.96M. The largest seller was HighTower Advisors, exiting entirely with an estimated $92K sold.

  • 52 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2020, up from 28 in Q3 2020.
  • Funds reported $127M of VistaGen Therapeutics stock for Q4 2020, up 5,238% quarter-over-quarter.
  • 28 funds opened new VistaGen Therapeutics positions in Q4 2020 and 4 closed out, a net change of +24 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2020 was NEA Management Company, an estimated $7.96M added.
  • The largest VistaGen Therapeutics seller in Q4 2020 was HighTower Advisors, an estimated $92K sold.

Based on aggregated 13F filings for Q4 2020.